Total trials
111
Active
23
Phase 3
5
Total enrollment
19,138
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylprednisolone | — | — | — | 3 | |||
| Atorvastatin 20mg | — | — | — | — | — | 1 | |
| anti obesity medication | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-03-31
- 2026-06-01
Top conditions
- Periodontitis7
- Periodontal Diseases7
- Graves Ophthalmopathy5
- Type 2 Diabetes3
- Obesity3
- Wound Heal2
- Premature Birth2
- Asthma2
Frequently asked questions about University of Pisa
- How many clinical trials does University of Pisa have on ClinicalTrials.gov?
- University of Pisa is listed as the lead sponsor on 111 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Pisa's trials are in Phase 3?
- 5 of University of Pisa's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Pisa focus on?
- University of Pisa's most-studied conditions on ClinicalTrials.gov are Periodontitis, Periodontal Diseases, Graves Ophthalmopathy, Type 2 Diabetes, Obesity.
- When are University of Pisa's next clinical trial readouts?
- University of Pisa has 3 upcoming primary-completion readouts tracked here; the soonest is “A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study”, expected around 2025-12-31.